Episode 560: MCAS, Chronic Lyme Disease, GLP-1 Agonists, Biofilms, and the Future of Precision Medicine — Dr. Tania Dempsey, MD

GLP-1 Agonists, MCAS, Lyme Disease, and the Future of Precision Medicine In this powerful Tick Boot Camp Podcast interview, Matt Sabatello sits down with Dr. Tania Dempsey, MD, a board-certified internal medicine physician and internationally recognized expert in Mast Cell Activation Syndrome (MCAS), Lyme disease, autoimmune conditions, and complex chronic illness. In this comprehensive conversation, Dr. Dempsey delivers one of the most forward-thinking and in-depth discussions ever featured on the podcast — connecting the dots between persistent symptoms after Lyme, immune dysregulation, biofilms, nervous system dysfunction, and groundbreaking research on GLP-1 receptor agonists as mast-cell stabilizers. This episode offers science, clinical insight, and — most importantly — hope for patients who have tried everything and are still struggling. Lyme Disease, MCAS, and Why Patients Stay Sick Why Treating Lyme Alone Is Often Not Enough Dr. Dempsey explains why many patients continue to experience inflammation, pain, neurological symptoms, and relapses even after treating Lyme disease and co-infections. According to her clinical experience, this is most often due to primary Mast Cell Activation Syndrome, not persistent infection alone. Key insight: > Lyme disease frequently acts as the trigger, but MCAS is often the driver of ongoing symptoms. Dr. Dempsey clarifies the critical difference between: Primary MCAS (pre-existing immune dysfunction worsened by infections) Secondary MCAS (rare; resolves completely once infection is treated) She notes that in decades of clinical practice, she has never seen true secondary MCAS fully resolve without ongoing mast-cell management. SOT Therapy: When, Why, and How It Works Best Dr. Dempsey provides a nuanced and experience-based explanation of Supportive Oligonucleotide Technique (SOT) for Lyme and co-infections. She addresses common criticism: One-time SOT treatments are rarely sufficient Chronic Lyme often involves multiple strains of Borrelia , Babesia , and Bartonella Her most successful cases involve: Repeated testing Sequential SOT treatments targeting specific strains Immune system support between rounds Adjunctive therapies such as herbs, antiparasitics, and mast-cell stabilization She shares a remarkable case of a young woman with severe neuropsychiatric symptoms who — after years of persistent SOT treatment combined with MCAS management — is now thriving, off psychiatric medications, and successfully completing college. Biofilms: Why They Matter in Chronic Infection Dr. Dempsey firmly states that biofilms are a critical barrier to recovery in chronically ill patients. Key points: Biofilms exist in the gut, sinuses, blood, and tissues They protect microbes from antibiotics, herbs, and immune attack Resistant biofilms may involve extracellular DNA (Z-DNA), discussed at ILADS Therapies discussed: Enzymes such as lumbrokinase and nattokinase Ozone therapy Therapeutic Plasma Exchange (TPE) for severe cases Her message is clear: if you cannot reach microbial reservoirs hidden in biofilms, infections cannot be fully controlled. GLP-1 Agonists, Immune Modulation, and Breakthrough MCAS Research GLP-1 Receptor Agonists as Mast-Cell Stabilizers Dr. Dempsey presents groundbreaking findings from her published case series: “The Utility of GLP-1 Receptor Agonists in Mast Cell Activation Syndrome” Key details: 47-patient case series Micro-dosing of GLP-1 agonists Primary medications used: tirzepatide (Mounjaro / Zepbound) and semaglutide (Ozempic / Wegovy) Unlike weight-loss protocols, Dr. Dempsey uses very low doses to target immune modulation — not appetite suppression. What GLP-1 Therapy Improved in MCAS & Lyme Patients Reported improvements included: Cognitive clarity and brain fog Chronic pain Neuropsychiatric symptoms Anxiety and depression Gastrointestinal symptoms Systemic inflammation Hormonal dysregulation In some cases, patients experienced improvement within one or two doses. Dr. Dempsey explains that mast cells express GLP-1 receptors, and activation sends a signal of safety, reducing inflammatory mediator release. Unexpected Findings: Muscle Mass and Antibody Reduction Contrary to common concerns, Dr. Dempsey observed: Preserved or increased muscle mass in the majority of patients Improved mitochondrial function and exercise tolerance Reduction in chronic antibody production (including Lyme Western Blot bands) She shares a striking case where a patient with long-standing positive Lyme antibodies saw antibody levels decline for the first time in over a decade after GLP-1 therapy — despite infection already being treated. This supports her hypothesis: > MCAS can drive persistent immune activation even when infection is no longer present. Side Effects, Screening & Who Should Not Use GLP-1s Potential side effects (usually mild): Nausea Delayed gastric emptying Occasional vomiting in sensitive patients Important clinical notes: Some patients respond better to semaglutide vs tirzepatide A small subset may require dose cycling or pulsing Antibody formation against GLP-1 drugs is a potential research focus Non-Pharmaceutical Alternatives to Increase GLP-1 Activity For patients who cannot tolerate medications, Dr. Dempsey outlines alternatives. Herbal & Supplement Options OptimumGLP Synergy (herbal blend designed to support GLP-1 signaling) Calocurb (GLP-1 supportive compound) These options may: Reduce inflammation Help stabilize appetite and blood sugar Calm mast-cell activity Diet-Based Strategies Dr. Dempsey explains why higher-protein and carnivore-leaning diets may benefit MCAS and Lyme patients: Protein and fat stimulate endogenous GLP-1 Reduced food triggers Improved metabolic stability Patients do not need to eat exclusively meat — but increasing high-quality protein intake is often beneficial. Nervous System, Trauma & Mast Cell Feedback Loops The episode explores how: Mast cells and nerves exist in a bidirectional feedback loop Chronic fight-or-flight worsens immune activation Therapies discussed: Limbic retraining programs ( Primal Trust , Gupta Program) Vagal nerve stimulation Apollo Neuro wearable Ketamine-assisted therapy Psychedelic microdosing (emerging area) Breaking the mast-cell / nervous-system loop is often essential for healing. Women’s Health, PCOS & Autoimmune Illness Dr. Dempsey shares a critical insight: > In her practice, every PCOS patient also has MCAS. She explains how: Mast cells respond to estrogen, progesterone, insulin, and cortisol Hormonal fluctuations can trigger MCAS flares MCAS may underlie PMS, PMDD, endometriosis, and reproductive pain syndromes GLP-1 therapy may offer new hope for women suffering from inflammatory gynecologic symptoms linked to Lyme and MCAS. Advocacy, ILADS & The Future of MCAS Research Dr. Dempsey discusses her work with: ILADS (International Lyme and Associated Diseases Society) ISMCAS (International Society for Mast Cell Activation Syndrome) ISMCAS goals include: Funding MCAS research Educating clinicians globally Supporting patients and advocacy efforts She encourages patients to: Educate themselves Share credible research with providers Move on from doctors unwilling to listen Final Takeaway This episode redefines what root-cause medicine truly means. Healing chronic Lyme disease often requires addressing: Immune dysregulation Mast cell activation Nervous system dysfunction Hormonal imbalance Metabolic inflammation Dr. Tania Dempsey offers a roadmap — grounded in science, compassion, and innovation — for patients